Literature DB >> 3172800

Extracorporeal membrane oxygenation in children. New trends.

A Trento1, A Thompson, R D Siewers, R A Orr, P Kochanek, B Fuhrman, J Frattallone, L B Beerman, D R Fischer, B P Griffith.   

Abstract

At the Children's Hospital of Pittsburgh the extracorporeal membrane oxygenation program was started in 1980. The results of our experience from 1980 to 1985 were previously reported. In the past 2 years 39 additional newborn infants have been treated with this modality, with an overall survival rate of 79% (31/39). This survival rate is much better than that obtained in 33 neonates who had been treated in the previous 5 years (54%; p less than 0.05). A new aspect of our extracorporeal membrane oxygenation program is the use of total apneic lung rest for persisting pulmonary interstitial emphysema during support with the oxygenator. Six neonates were treated with this technique because of worsening pulmonary interstitial emphysema during extracorporeal circulation. Five of them survived. Another indication for extracorporeal membrane oxygenation in our pediatric population has been left ventricular or biventricular failure after cardiopulmonary bypass. Four of our seven patients treated for this indication are long-term survivors. At present, because of the impossibility of using other forms of left ventricular assist devices in the pediatric population, it seems that extracorporeal membrane oxygenation is the most effective treatment for left ventricular failure after cardiopulmonary bypass. From our experience, even in the absence of long-term follow-up of patients supported with extracorporeal membrane oxygenation, it appears that the benefits of this therapeutic modality far exceed the risks in the high-risk population for which it is being used.

Entities:  

Mesh:

Year:  1988        PMID: 3172800

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

Review 1.  Extracorporeal membrane oxygenation.

Authors:  A W Sosnowski; S J Bonser; D J Field; T R Graham; R K Firmin
Journal:  BMJ       Date:  1990-08-11

2.  Extracorporeal membrane oxygenation and tracheobronchial foreign body in an infant.

Authors:  Y Inagaki; T Hamanaka; M Takenoshita; T Mashimo; I Yoshiya
Journal:  J Anesth       Date:  1995-12       Impact factor: 2.078

3.  Left ventricular performance in neonates on extracorporeal membrane oxygenation.

Authors:  F Berdjis; M Takahashi; A B Lewis
Journal:  Pediatr Cardiol       Date:  1992-07       Impact factor: 1.655

4.  In vitro characterization and performance testing of the ension pediatric cardiopulmonary assist system.

Authors:  George M Pantalos; Tim Horrell; Tracey Merkley; Sarina Sahetya; Jeff Speakman; Greg Johnson; Mark Gartner
Journal:  ASAIO J       Date:  2009 May-Jun       Impact factor: 2.872

5.  Extracorporeal membrane oxygenation (ECMO) for acute exacerbations of chronic obstructive pulmonary disease: care modalities, experience, and precautions.

Authors:  Yaoji Wang; Pingping Cao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

6.  Congenital lobar emphysema in neonates: Anaesthetic challenges.

Authors:  Mridu Paban Nath; Sachin Gupta; Ashish Kumar; Anulekha Chakrabarty
Journal:  Indian J Anaesth       Date:  2011-05

7.  Congenital lobar emphysema: A modified approach to anesthetic management.

Authors:  Malathi C Nandihalli; Srinivas H Thammaiah; Nalini Kotekar; Prashanth R Putran
Journal:  Indian J Crit Care Med       Date:  2015-01

8.  Diffuse persistent pulmonary interstitial emphysema secondary to mechanical ventilation in bronchiolitis.

Authors:  Blanca Toledo Del Castillo; Isabel Gordillo; Elena Rubio García; Sarah Nicole Fernández Lafever; Rafael Gonzalez Cortés; Javier Urbano Villaescusa; Jorge López González; María José Solana García; Jesús López-Herce Cid
Journal:  BMC Pulm Med       Date:  2016-11-03       Impact factor: 3.317

Review 9.  Management of respiratory failure.

Authors:  M Singh; L Kumar
Journal:  Indian J Pediatr       Date:  1996 Jan-Feb       Impact factor: 1.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.